Dr David Fischer

David holds a degree in Chemistry and a PhD in Molecular Genetics, both from Leiden University in The Netherlands. After six years of post-doctoral fellowships at the Netherlands Institute for Neuroscience in Amsterdam and the Free University Amsterdam he joined Galapagos. Charles River acquired the service operations from Galapagos in 2014.
As Chief Technology Officer for Early Discovery, I both work with our drug discovery unit, as well as across the Charles River business units to help expedite our clients’ drug discovery and development programs. Furthermore, I work with our strategic partners to bring in cutting edge drug discovery platforms and technologies. In addition, I collaborate together with our CRL colleagues in pharmacology, safety assessment and CDMO on personalized (“n=1”) drug therapies, often for single patients with an ultra-rare disease.